Global ETD Search

41	Expression von polyspezifischen Transportern in renalen Tumoren und ihre Bedeutung für die Chemotherapie / The expression of polyspecific transporters in renal tumors and their role in chemotherapeutical treatment Shnitsar, Volodymyr 24 April 2008 (has links) No description available. 570 Biowissenschaften, Biologie WI 000 MED 280 MED 351 MED 353 MED 424 Mathematics and Natural Science SLC RCC Irinotekan Melphalan Vincristin SLC RCC Irinotecan Melphalan Vincristine 42.15 42.17 44.38 48.81
42	The Combination of Carboxylesterase-Expressing Oncolytic Vaccinia Virus and Irinotecan Becker, Michelle Caitlin 14 January 2013 (has links) This project combines oncolytic Vaccinia virus (VV) with irinotecan (CPT-11) for the treatment of cancer. VV can infect, replicate in and destroy cancer cells, yet leave healthy cells relatively unaffected. CPT-11 is a chemotherapeutic of which ~5% is converted to the more active chemotherapeutic SN-38 by endogenous carboxylesterase (CE) enzymes. SN-38 is a topoisomerase I inhibitor that induces DNA double strand breaks, leading to growth arrest and apoptosis. Consequently, VV has been engineered to express a more effective isoform of the CE enzyme. The virus’ tumour tropism should restrict enhanced conversion of CPT-11 to the tumour. Neither CPT-11 nor SN-38 interfered with VV replication or spread. Engineered recombinants expressed CE enzyme which, when combined with CPT-11, produced DNA double strand breaks and cancer cell death. In vitro, the combination of CE-virus and CPT-11 killed more K-562 cancer cells than its non-CE counterpart and CPT-11. Cancer Oncolytic virus Vaccinia virus Carboxylesterase Irinotecan CPT-11 Gene-directed enzyme prodrug therapy Vascular endothelial growth factor Angiogenesis Virus delivery Virus spread Plaque purification Virus aggregation Virus filtration
43	The Combination of Carboxylesterase-Expressing Oncolytic Vaccinia Virus and Irinotecan Becker, Michelle Caitlin January 2013 (has links) This project combines oncolytic Vaccinia virus (VV) with irinotecan (CPT-11) for the treatment of cancer. VV can infect, replicate in and destroy cancer cells, yet leave healthy cells relatively unaffected. CPT-11 is a chemotherapeutic of which ~5% is converted to the more active chemotherapeutic SN-38 by endogenous carboxylesterase (CE) enzymes. SN-38 is a topoisomerase I inhibitor that induces DNA double strand breaks, leading to growth arrest and apoptosis. Consequently, VV has been engineered to express a more effective isoform of the CE enzyme. The virus’ tumour tropism should restrict enhanced conversion of CPT-11 to the tumour. Neither CPT-11 nor SN-38 interfered with VV replication or spread. Engineered recombinants expressed CE enzyme which, when combined with CPT-11, produced DNA double strand breaks and cancer cell death. In vitro, the combination of CE-virus and CPT-11 killed more K-562 cancer cells than its non-CE counterpart and CPT-11. Cancer Oncolytic virus Vaccinia virus Carboxylesterase Irinotecan CPT-11 Gene-directed enzyme prodrug therapy Vascular endothelial growth factor Angiogenesis Virus delivery Virus spread Plaque purification Virus aggregation Virus filtration
44	Correlating Irinotecan and Capecitabine Treatment for Colorectal Cancer to Gene Expression, Polymorphisms, and Clinical Outcomes Hinkle, David T., IV. 16 March 2011 (has links) Indiana University-Purdue University Indianapolis (IUPUI) / Colorectal cancer is the third most common type of cancer and the third most common cause of cancer-related mortality. There are three types of treatment available to patients, either individually or in combination. Treatments are radiation, chemotherapy, and surgery. In a Phase II clinical trial at IUSM, a multimodality approach was chosen. The patients with locally advanced rectal cancer received preoperative treatment with capecitabine and irinotecan (CPT-11) combination followed by chemoradiation with capecitabine and finally surgery to improve response and decrease local recurrence. Irinotecan and Capecitabine are both prodrugs activated in vivo to SN-38 and 5-FU, respectively. Identification of the molecular markers for 5-FU and Irinotecan efficacy and toxicity is important for the development of more efficient and less toxic treatment strategies for patients with colorectal cancer. The goal of this study was to determine the expression levels of the genes involved in activation and metabolism of capecitabine and irinotecan in pre and post treatment specimens from these patients. The genes quantitated by real-time PCR were carboxylesterase 1 and 2 (CES1 and CES2), thymidylate synthase (TS), β-glucoronidase (β-GUS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD) and topoisomerase I (Topo I). The UGT1A128 polymorphism in UDP glucuronosyltransferase 1 is associated with SN-38 toxicity. Therefore, the UGT1A128 polymorphism status in patients was determined by PCR-sequencing. Correlative analysis of gene expression and UGT1A128 mutation with clinical outcome in this Phase II study was completed. Irinotecan CPT-11 Capecitabine DPD B-GUS TS TP TOPO I UGT1A128 Colorectal cancer SN-38 Rectum -- Cancer -- Adjuvant treatment Prodrugs Gene expression
45	Einfluss des Transkriptionsfaktors B-cell lymphoma 6 (BCL6) auf die Expression renaler Transportproteine / The effect of the transcription factor B-cell lymphoma 6 (BCL6) on the expression of renal transport proteins Millé, Aline Noel 07 November 2016 (has links) No description available. 610 Nierenzellkarzinom Transkriptionsfaktor renale Transportproteine humane Organische-Anionen-Transporter humane Organische-Kationen-Transporter Chemoresistenz Efflux-Transporter Influx-Transporter RCC B-cell lymphoma 6 BCL6 renal cell carcinoma influx transporter efflux transporter ATP- binding cassette solute carrier (SLC) family OAT OCT MDR1 MRP2 chemoresistance 5-FU Irinotecan Oxaliplatin proximal tubule transcription factor Medizin (PPN619874732)

Page generated in 0.0474 seconds